IN2012DN03127A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03127A
IN2012DN03127A IN3127DEN2012A IN2012DN03127A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A IN 3127DEN2012 A IN3127DEN2012 A IN 3127DEN2012A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Zhanggui Wu
Original Assignee
Zhanggui Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhanggui Wu filed Critical Zhanggui Wu
Publication of IN2012DN03127A publication Critical patent/IN2012DN03127A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3127DEN2012 2009-09-18 2012-04-11 IN2012DN03127A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24354909P 2009-09-18 2009-09-18
PCT/US2010/049199 WO2011035077A1 (fr) 2009-09-18 2010-09-17 Nouveaux composés et leur utilisation thérapeutique pour une inhibition de protéine kinase

Publications (1)

Publication Number Publication Date
IN2012DN03127A true IN2012DN03127A (fr) 2015-09-18

Family

ID=43759014

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3127DEN2012 IN2012DN03127A (fr) 2009-09-18 2012-04-11

Country Status (14)

Country Link
US (2) US8815863B2 (fr)
EP (2) EP2826780B1 (fr)
JP (1) JP6155026B2 (fr)
CN (2) CN102711475B (fr)
AU (2) AU2010295492B2 (fr)
BR (1) BR112012006062A2 (fr)
CA (1) CA2774367C (fr)
ES (2) ES2481791T3 (fr)
HK (1) HK1170908A1 (fr)
IN (1) IN2012DN03127A (fr)
MX (1) MX2012003286A (fr)
NZ (1) NZ599453A (fr)
RU (1) RU2012109220A (fr)
WO (1) WO2011035077A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774367C (fr) * 2009-09-18 2018-07-10 Zhanggui Wu Composes et leur utilisation therapeutique en vue de l'inhibition de la proteine kinase
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2021141980A1 (fr) * 2020-01-07 2021-07-15 Fan Wu Polythérapie anticancéreuse utilisant un inhibiteur de chk
JP7407298B2 (ja) * 2020-03-04 2023-12-28 ファロス・アイバイオ・カンパニー・リミテッド 2,3,5-置換されたチオフェン化合物の卵巣癌の予防、改善または治療用途
CN115605484A (zh) * 2020-04-17 2023-01-13 浙江医药股份有限公司新昌制药厂(Cn) 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用
CN116332960A (zh) * 2021-12-23 2023-06-27 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
CN117263950A (zh) * 2022-06-13 2023-12-22 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
CN117003736B (zh) * 2023-10-07 2023-12-15 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029241A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de chk1 kinase
WO2003028731A1 (fr) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de kinase chk1
AU2003270701B2 (en) * 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
CN1950378A (zh) * 2004-05-04 2007-04-18 霍夫曼-拉罗奇有限公司 作为ikk抑制剂的噻吩并哒嗪类化合物
EP1745050A1 (fr) * 2004-05-04 2007-01-24 F.Hoffmann-La Roche Ag Thienopyridines utilisees en tant qu'inhibiteurs des ikk
MX2007012448A (es) * 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
CN101189243A (zh) 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
CA2649543A1 (fr) * 2006-04-21 2007-11-01 Amgen Inc. Composes de thieno-[2,3-d]pyrimidine et de thienopyridazine et procedes d'utilisation de ceux-ci
US8241918B2 (en) 2006-07-03 2012-08-14 Koninklijke Philips Electronics N.A. Beverage dispensing device with freshness indicator
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CA2774367C (fr) * 2009-09-18 2018-07-10 Zhanggui Wu Composes et leur utilisation therapeutique en vue de l'inhibition de la proteine kinase

Also Published As

Publication number Publication date
EP2477496B1 (fr) 2014-04-16
AU2010295492B2 (en) 2016-05-05
JP6155026B2 (ja) 2017-06-28
EP2826780A1 (fr) 2015-01-21
WO2011035077A1 (fr) 2011-03-24
ES2587509T3 (es) 2016-10-25
CN104628741A (zh) 2015-05-20
BR112012006062A2 (pt) 2015-09-08
CN102711475B (zh) 2015-01-28
ES2481791T3 (es) 2014-07-31
US8815863B2 (en) 2014-08-26
US20120232082A1 (en) 2012-09-13
JP2013505254A (ja) 2013-02-14
AU2016204867B2 (en) 2017-02-16
US9487539B2 (en) 2016-11-08
MX2012003286A (es) 2012-06-19
AU2016204867A1 (en) 2016-07-28
CA2774367C (fr) 2018-07-10
NZ599453A (en) 2014-03-28
US20150072987A1 (en) 2015-03-12
EP2477496A1 (fr) 2012-07-25
RU2012109220A (ru) 2013-10-27
EP2826780B1 (fr) 2016-06-01
AU2010295492A1 (en) 2012-05-03
CN102711475A (zh) 2012-10-03
EP2477496A4 (fr) 2013-02-27
CA2774367A1 (fr) 2011-03-24
HK1170908A1 (en) 2013-03-15

Similar Documents

Publication Publication Date Title
BR112012012396A2 (fr)
BRPI1009599A2 (fr)
BRPI0925311A2 (fr)
BRPI0924307A2 (fr)
BR112012003080A2 (fr)
BR122021004633A2 (fr)
BR122017024704A2 (fr)
BR112012012487A2 (fr)
BR112012003853A2 (fr)
BR112012012080A2 (fr)
BR112012009797A2 (fr)
BR112012009703A2 (fr)
BR112012007656A2 (fr)
BR122019005883A2 (fr)
BR112012002627A2 (fr)
BR112012001263A2 (fr)
BR112012014856A2 (fr)
BRPI0924534A2 (fr)
BR112012007654A2 (fr)
BR112012007672A2 (fr)
BRPI0924617A2 (fr)
BR122017013721A2 (fr)
BR112012016234A2 (fr)
BR112012007671A2 (fr)
BRPI0925022A2 (fr)